Serum pentraxin and E-selectin levels are associated with outcomes in patients with acute myocardial infarction who undergo percutaneous coronary intervention

Introduction: Despite reperfusion by primary percutaneous coronary intervention (PCI) in acute myocardial infarction (AMI) some patients develop left ventricular dysfunction. The extent of cardiac injury is associated with the inflammation and the reperfusion damage. An overly long inflammatory phase can cause sustained myocardial damage and improper healing, leading to remodelling and ventricular dilatation. We sought to elucidate whether proinflammatory proteins, cytokines and adhesion molecules that participate in the processes of inflammation, ischaemia-reperfusion injury and postmyocardial left ventricular remodelling are associated with the major adverse cardiovascular events (MACE) (all-cause mortality or AMI) during the two-year follow-up. Material and methods: It is a prospective analysis of patients with AMI admitted to the cardiology ward who underwent PCI between December 2018 and April 2019. The Luminex Multiplex Assay was used to measure serum biomarker concentrations (Bio-Plex System 200, Bio-Rad, USA), and the data were analysed using Bio-Plex Manager Software. Results: The median age was 66 (58–74), and 31.8% were women. The end-point was reached in 53 (37.9%) patients. Multivariate analysis found that serum pentraxin-3 [odds ratio (OR) 1.295 (1.175–1.443), p < 0.001] and E-selectin [OR 1.539 (1.151–2.265), p = 0.03] concentrations were associated with MACE. Conclusions: Higher pentraxin and E-selectin serum concentrations are independently associated with all-cause mortality or myocardial infarction in the analysed population during the two-year follow-up.